Chikungunya vaccine protects against virus in small Phase I study

An article from FierceVaccines
August 20, 2014
With recent outbreaks in the Caribbean and the Pacific, the U.S. Centers for Disease Control and Prevention (CDC) is concerned that the number of chikungunya cases among travelers will continue to rise. But results from an early-stage clinical trial point to a promising vaccine that may be able to prevent transmission of the disease.
 
In a Phase I clinical trial of 25 adult volunteers, the experimental vaccine showed protection against the virus, eliciting neutralizing antibodies in all participants, according to a study appearing Aug. 15 in The Lancet.
 
Trial subjects received one of three different doses of the vaccine--an initial jab, a second one at four weeks and a third one at 20 weeks after the initial injection. Neutralizing antibodies were detected in a majority of the subjects after the first shot. After all three jabs, all dose groups had developed high levels of antibodies against chikungunya virus.
 
Read more here.
Common Disease Taxonomy: 
0